Genmab

MA BD deal handshake cooperation collaboration business deal
Pharma

2025's top biopharma M&A deals

Looming patent expirations and a thawing of the biotech investment scene prompted drug developers of all stripes to pull out their checkbooks in 2025.
Epkinly

Genmab touts new data that set up Epkinly for FL expansion

Aug 8, 2025 7:25am
Asia

Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia

Mar 28, 2025 9:28am
Lunsumio

ASH: Roche's subQ Lunsumio matches IV version in lymphoma

Dec 9, 2024 3:16pm
Regeneron

EU signs off on Regeneron's T-cell engager for 2 blood cancers

Aug 26, 2024 10:35am
boardroom

Genmab shuffles C-Suite as portfolio grows

Aug 19, 2024 10:08am